Modern Approaches to Pharmacotherapy of Migraine

T.S. Mishchenko, V.N. Mishchenko

Abstract


The article deals with one of the varieties of headache — migraine. Stages and criteria for successful treatment of migraine attacks are described. Drugs of choice for the treatment of mild-to-moderate migraine attacks are nonsteroidal anti-inflammatory drugs (NSAIDs). One of the most effective NSAIDs for the treatment and prevention of migraine is naproxen sodium (Nalgesin Forte). If the attacks are not relieved by using NSAIDs, drugs with a more pronounced specific action (triptans) should be administered. Drug preventive therapy is justified in frequent (at least 3 times a month) severe migraine attacks, as well as in the presence of comorbidities.

Keywords


headache; migraine; treatment; naproxen sodium; triptans; prevention

References


Lipton R.B., Bigal M.E. Migraine: Epidemiology, impact, and risk factors for progression // Headache. — 2005. — 45 (Suppl. 1). — P. 3-13.

Headache Classification Committee for the International Headache Society. The international classification of headache disorders: Second edition // Cephalalgia. — 2004. — 24 (Suppl. 1). — P. 1-151.

Kelman L., Tanis D. The relationship between migraine pain and other associated symptoms // Cephalalgia. — 2006. — 26. — P. 548-553.

Landy S. Migraine throughout the life cycle. Treatment through the ages // Neurology. — 2004. — 62 (Suppl. 2). — P. 2-8.

Jenkins D., Feniuk W., Humphrey P. Characterization of the prostanoid receptor types involved in mediating calcitonin generelated peptide release from cultured rat trigeminal neurones // Br. J. Pharmacol. — 2001. — 134. — P. 1296-1302.

Stephanie A., Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system // J. Headache Pain. — 2008. — 9. — P. 5-12.

Beithon J. et al. Institute for Clinical Systems Improvement // Diagnosis and Treatment of Headache. — 2013.

Tfelt-Hansen P., Block G. et al. Guidelines for controlled trials of drugs in migraine: second edition // Cephalalgia. — 2000. — 20. — P. 765-786.

Lipton R., Bigal M., Diamond M. et al. Migraine prevalence, disease burden, and the need for preventive therapy // Neurology. — 2007. — 68. — P. 343-349.

Evers S., Afra J., Frese A. et al. EFNS guideline on the drug treatment of migraine — revised report of an EFNS task force // European Journal of Neurology. — 2009. — 16. — P. 968-981.

Diener H., Bussone G., Liano H. et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks // Cephalalgia. — 2004. — 24. — P. 947-954.

Dahlof C., Bjorkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine // Cephalalgia. — 1993. — 13. — P. 117-123.

Gobel H., Heinze A., Niederberger U. et al. Efficacy of phenazone in the treatment of acute migraine attacks: a double-blind, placebo-controlled, randomized study // Cephalalgia. — 2004. — 24. — P. 888-893.

Tulunay F., Ergun H., Gulmez S. et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treat ment of acute migraine attacks: a double-blind, cross over, randomized, placebo-controlled, multi-center study // Funct. Neurol. — 2004. — 19. — P. 197-202.

Myllyla V., Havanka H., Herrala L. et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study // Headache. — 1998. — 38. — P. 201-207.

Lipton R., Baggish J., Stewart W., Codispoti J. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study // Arch. Intern. Med. — 2000. — 160. — P. 3486-3492.

Diener H., Pfaffenrath V., Pageler L. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multi-centre, randomized, double-blind, single-dose, placebo-controlled parallel group study // Cephalalgia. — 2005. — 25. — P. 776-787.

Johnson E., Ratcliffe D., Wilkinson M. Naproxen sodium in the treatment of migraine // Cephalalgia. — 1985. — 5. — P. 5-10.

Rasmussen M., Binzer M. Non-steroidal antiinflammatory drugs in the treatment of migraine // Current Medical Research and Opinion. — 2001. — 17 (Suppl. 1). — P. 26-29.

Brandes J., Kudrow D., Stark S. et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial // JAMA. — 2007. — 297. — P. 1443-1454.

Johnson E., Ratcliffe D., Wilkinson M. Naproxen sodium in the treatment of migraine // Cephalalgia. — 1985. — 5. — P. 5-10.

Nestvold K., Kloster R., Partinen M., Sulkava R. Treatment of acute migraine attack: Naproxen and placebo compared // Cephalalgia. — 1985. — 5. — P. 115-119.

Ziegler D., Ellis D. Naproxen in prophylaxis of migraine // Arch. Neurol. — 1985. — 42. — P. 582-584.

Guidelines of the British Association for the study of ­headache. — 2010. — http://www.bash.org.uk/guidelines/primary-headache-disorders/

Sven Trelle, Stephan Reichenbach, Simon Wandel, Pius Hildebrand, Beatrice Tschannen, Peter M. Villiger, Matthias Egger, Peter Jüni. Кардиоваскулярная безопасность нестероидных противовоспалительных препаратов: сетевой метаанализ // Международный неврологический журнал. — 2013. — № 1(33). — С. 62-77.

Friedman B., Corbo J., Lipton R. et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines // Neurology. — 2005. — 64. — P. 463-468.

Ferrari M., Roon K., Lipton R., Goadsby P. Oral triptans (serotonin 5-HT1B//1D agonists) in acute migraine treatment: a meta-analysis of 53 trials // Lancet. — 2001. — 358. — P. 1668-1675.

Lainez M., Galvan J., Heras J., Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy // Eur. J. Neurol. — 2007. — 14. — P. 269-275.

Diamond M., Hettiarachchi J., Hilliard B., Sands G., Nett R. Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders // Headache. — 2004. — 44. — P. 209-216.

Diener H. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multi-center, parallel group study // Cephalalgia. — 1999. — 19. — P. 581-588.

Bigal M., Serrano D., Buse D. et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study // Headache. — 2008. — 48. — P. 1157-1168.

Limmroth V., Kazarawa S., Fritsche G., Diener H. Headache after frequent use of new serotonin agonists zolmitriptan and naratriptan // Lancet. — 1999. — P. 353-378.

Katsarava Z., Fritsche G., Muessig M. et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs // Neurology. — 2001. — 57. — P. 1694-1698.

Brandes J., Kudrow D., Stark S. et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial // JAMA. — 2007. — 297. — P. 1443-1454.

Bates D., Ashford E., Dawson R. et al. Subcutaneous sumatriptan during the migraine aura // Neurology. — 1994. — 44. — P. 1587-1592.

Olesen J., Diener H., Schoenen J., Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine // Eur. J. Neurol. — 2004. — 11. — P. 671-677.

Edwards K., Norton J., Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache // Headache. — 2001. — 41. — P. 976-980.

Leniger T., Pageler L., Stude P. et al. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks // Headache. — 2005. — 45. — P. 42-46.

Soyka D., Taneri Z., Oestreich W., Schmidt R. Flunarizine i.v. in the acute treatment of the migraine attack. A double-blind placebo-controlled study // Cephalalgia. — 1988. — 8 (Suppl. 8). — P. 35-40.

Silberstein S., Freitag F., Rozen T. et al. Tramadol acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial // Headache. — 2005. — 45. — P. 1317-1327.

Sorensen P., Larsen B., Rasmussen M. et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, rando-mized parallel group study of efficacy and tolerability // Headache. — 1991. — 31. — P. 650-657.

Gawel M., Kreeft J., Nelson R. et al. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine // Can. J. Neurol. Sci. — 1992. — 19. — P. 340-345.

Worz R., Reinhardt-Benmalek B., Grotemeyer K. Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura — a randomized double-blind cross-over multicenter study // Cephalalgia. — 1991. — 11 (Suppl. 11) — P. 152-153.

Stellar S., Ahrens S., Meibohm A., Reines S. Migraine prevention with timolol. A double-blind crossover study // JAMA. — 1984. — 252. — P. 2576-2580.

Johannsson V., Nilsson L., Widelius T. et al. Atenolol in migraine prophylaxis a double-blind cross-over multi- centrestud // Headache. — 1987. — 27. — P. 372-374.

Louis P. A double-blind placebo-controlled prophylactic study of flunarizine in migraine // Headache. — 1981. — 21. — P. 235-239.

Diamond S., Schenbaum H. Flunarizine, a calcium channel blocker, in the prophylactic treatment of migraine // Headache. — 1983. — 23. — P. 39-42.

Gerber W., Schellenberg R., Thom M. et al. Cyclande — late versus propranolol in the prophylaxis of migraine — a double-blind placebo-controlled study // Funct. Neurol. — 1995. — 10. — P. 27-35.

Diener H., Foh M., Iaccarino C. et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol // Cephalalgia. — 1996. — 16. — P. 441-447.

Freitag F., Collins S., Carlson H. et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis // Neurology. — 2002. — 58. — P. 1652-1659.

Brandes J., Saper J., Diamond M. et al. Topiramate for migraine prevention: a randomized controlled trial // JAMA. — 2004. — 291. — P. 965-973.

Diener H., Tfelt-Hansen P., Dahlof C. et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control // J. Neurol. — 2004. — 251. — P. 943-950.

Steiner T., Findley L., Yuen A. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura // Cephalalgia. — 1997. — 17. — P. 109-112.

Mathew N., Rapoport A., Saper J. et al. Efficacy of gabapentin in migraine prophylaxis // Headache. — 2001. — 41. — P. 119-128.

Silberstein S., Saper J., Berenson F. et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study // Neurology. — 2008. — 70. — P. 548-555.

Peto R., Gray R., Collins R. et al. Randomised trial of prophylactic daily aspirin in male British doctors // BMJ. — 1988. — 296. — P. 313-316.

Buring J., Peto R., Hennekens C. Low-dose aspirin for migraine prophylaxis // JAMA. — 1990. — 264. — P. 1711-1713.

Welch K., Ellis D., Keenan P. Successful migraine prophylaxis with naproxen sodium // Neurology. — 1985. — 35. — P. 1304-1310.

Bellavance A., Meloche J. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis // Headache. — 1990. — 30. — P. 710-715.

McGettigan P., Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies // PLoS Med. — 2011. — 8(9): e1001098. — P. 1-18.




DOI: https://doi.org/10.22141/2224-0713.3.81.2016.77644

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта